Search

Your search keyword '"Boos, Joachim"' showing total 557 results
Start Over Author "Boos, Joachim" Search Limiters Academic (Peer-Reviewed) Journals
557 results on '"Boos, Joachim"'

4. Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study.

Author

Conter, Valentino, Valsecchi, Maria Grazia, Cario, Gunnar, Zimmermann, Martin, Attarbaschi, Andishe, Stary, Jan, Niggli, Felix, Dalla Pozza, Luciano, Elitzur, Sarah, Silvestri, Daniela, Locatelli, Franco, Möricke, Anja, Engstler, Gernot, Smisek, Petr, Bodmer, Nicole, Barbaric, Draga, Izraeli, Shai, Rizzari, Carmelo, Boos, Joachim, and Buldini, Barbara

Published
2024
Full Text
View/download PDF

6. Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscow–Berlin 2002

Author

Karachunskiy, Alexander, Tallen, Gesche, Roumiantseva, Julia, Lagoiko, Svetlana, Chervova, Almira, von Stackelberg, Arend, Aleinikova, Olga, Bydanov, Oleg, Bajdun, Lyudmila, Nasedkina, Tatiana, Korepanova, Natalia, Kuznetsov, Sergei, Novichkova, Galina, Goroshkova, Marina, Litvinov, Dmitry, Myakova, Natalia, Ponomareva, Natalia, Inyushkina, Evgeniya, Kondratchik, Konstantin, Abugova, Julia, Fechina, Larisa, Arakaev, Oleg, Karelin, Alexander, Lebedev, Vladimir, Judina, Natalia, Scharapova, Gusel, Spichak, Irina, Shamardina, Anastasia, Ryskal, Olga, Shapochnik, Alexander, Rumjanzew, Alexander, Boos, Joachim, Henze, Günter, and for the ALL-MB study group

Published
2019
Full Text
View/download PDF

7. Hypersensitivity Reactions to Native E. coli L-asparaginase in Children With Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction

Author

Möricke, Anja, primary, Rizzari, Carmelo, additional, Alten, Julia, additional, Attarbaschi, Andishe, additional, Beier, Rita, additional, Biondi, Andrea, additional, Burkhardt, Birgit, additional, Bodmer, Nicole, additional, Boos, Joachim, additional, Cario, Gunnar, additional, Conter, Valentino, additional, Flotho, Christian, additional, Kulozik, Andreas, additional, Lanvers-Kaminsky, Claudia, additional, Mann, Georg, additional, Niggli, Felix, additional, Silvestri, Daniela, additional, von Stackelberg, Arend, additional, Stanulla, Martin, additional, Valsecchi, Maria-Grazia, additional, Schrappe, Martin, additional, and Zimmermann, Martin, additional

Published
2023
Full Text
View/download PDF

10. Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 Study

Author

Würthwein, Gudrun, Lanvers-Kaminsky, Claudia, Gerss, Joachim, Möricke, Anja, Zimmermann, Martin, Stary, Jan, Smisek, Petr, Attarbaschi, Andishe, Nath, Christa, Zucchetti, Massimo, Rizzari, Carmelo, Schrappe, Martin, and Boos, Joachim

Published
2020
Full Text
View/download PDF

17. Hypersensitivity Reactions to Native E. coli L-asparaginase in Children With Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction

Author

Möricke, Anja, Rizzari, Carmelo; https://orcid.org/0000-0002-4828-3893, Alten, Julia, Attarbaschi, Andishe; https://orcid.org/0000-0002-9285-6898, Beier, Rita, Biondi, Andrea; https://orcid.org/0000-0002-6757-6173, Burkhardt, Birgit; https://orcid.org/0000-0002-1151-829X, Bodmer, Nicole, Boos, Joachim, Cario, Gunnar, Conter, Valentino; https://orcid.org/0000-0001-5697-4929, Flotho, Christian, Kulozik, Andreas; https://orcid.org/0000-0003-1953-0848, Lanvers-Kaminsky, Claudia, Mann, Georg, Niggli, Felix; https://orcid.org/0000-0002-7553-3712, Silvestri, Daniela, von Stackelberg, Arend, Stanulla, Martin; https://orcid.org/0000-0002-3834-0727, Valsecchi, Maria-Grazia, Schrappe, Martin; https://orcid.org/0000-0003-0034-5845, Zimmermann, Martin; https://orcid.org/0000-0002-0365-3512, Möricke, Anja, Rizzari, Carmelo; https://orcid.org/0000-0002-4828-3893, Alten, Julia, Attarbaschi, Andishe; https://orcid.org/0000-0002-9285-6898, Beier, Rita, Biondi, Andrea; https://orcid.org/0000-0002-6757-6173, Burkhardt, Birgit; https://orcid.org/0000-0002-1151-829X, Bodmer, Nicole, Boos, Joachim, Cario, Gunnar, Conter, Valentino; https://orcid.org/0000-0001-5697-4929, Flotho, Christian, Kulozik, Andreas; https://orcid.org/0000-0003-1953-0848, Lanvers-Kaminsky, Claudia, Mann, Georg, Niggli, Felix; https://orcid.org/0000-0002-7553-3712, Silvestri, Daniela, von Stackelberg, Arend, Stanulla, Martin; https://orcid.org/0000-0002-3834-0727, Valsecchi, Maria-Grazia, Schrappe, Martin; https://orcid.org/0000-0003-0034-5845, and Zimmermann, Martin; https://orcid.org/0000-0002-0365-3512

Published
2023

18. Bioanalysis of doxorubicin aglycone metabolites in human plasma samples–implications for doxorubicin drug monitoring

Author

Siebel, Christian, Lanvers‑Kaminsky, Claudia, Würthwein, Gudrun, Hempel, Georg, Boos, Joachim, and Universitäts- und Landesbibliothek Münster

Subjects
610 Medicine and health, lcsh:R, lcsh:Medicine, Article, Plasma, Oncology, Doxorubicin, Medicine and health, Humans, Chemotherapy, lcsh:Q, ddc:610, Drug Monitoring, lcsh:Science, Chromatography, High Pressure Liquid
Abstract

The widespread clinical use of the cytostatic doxorubicin together with the induction of chronic cardiomyopathy necessitates the conduct of further pharmacokinetic trials. Novel analytical technologies suitable for point-of-care applications can facilitate drug level analyses but might be prone to interferences from structurally similar compounds. Besides the alcohol metabolite doxorubicinol, aglycone metabolites of doxorubicin might affect its determination in plasma. To evaluate their analytical relevance, a validated HPLC method for the quantification of doxorubicin, doxorubicinol and four aglycones was used. The degradation pattern of doxorubicin in plasma under long-term storage was analysed with respect to the formation of aglycone products. In addition, overall 50 clinical samples obtained within the EPOC-MS-001-Doxo trial were analysed. Substantial degradation of doxorubicin in plasma occurred within a storage period of one year, but this did not lead to the formation of aglycones. In clinical samples, 7-deoxydoxorubicinolone was the major aglycone detectable in 35/50 samples and a concentration range of 1.0–12.7 μg L^−1. If at all, the other aglycones were only determined in very low concentrations. Therefore, analytical interferences from aglycones seem to be unlikely with the exception of 7-deoxydoxorubicinolone whose concentration accounted for up to 65% of the doxorubicin concentration in the clinical samples analysed., Finanziert über die DEAL-Vereinbarung mit Wiley 2019-2022.

Published
2023

23. Hypersensitivity Reactions to Native E. coli L-Asparaginase in Children with Acute Lymphoblastic Leukemia May Vary By Treatment Schedule and Type of Glucocorticoid in Induction: Results of Trial ALL-BFM 2000

Author

Möricke, Anja, primary, Schrappe, Martin, additional, Rizzari, Carmelo, additional, Alten, Julia, additional, Attarbaschi, Andishe, additional, Beier, Rita, additional, Biondi, Andrea, additional, Burkhardt, Birgit, additional, Bodmer, Nicole, additional, Boos, Joachim, additional, Cario, Gunnar, additional, Conter, Valentino, additional, Flotho, Christian, additional, Kulozik, Andreas E., additional, Lanvers-Kaminsky, Claudia, additional, Mann, Georg, additional, Niggli, Felix, additional, Silvestri, Daniela, additional, von Stackelberg, Arend, additional, Stanulla, Martin, additional, Valsecchi, Maria Grazia, additional, and Zimmermann, Martin, additional

Published
2022
Full Text
View/download PDF

24. Impact of Additional Intensive L-Asparaginase Therapy during Consolidation Phase for High-Risk Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial in the AIEOP-BFM ALL 2009 Protocol

Author

Conter, Valentino, primary, Valsecchi, Maria Grazia, additional, Cario, Gunnar, additional, Zimmermann, Martin, additional, Attarbaschi, Andishe, additional, Stary, Jan, additional, Niggli, Felix, additional, Dalla Pozza, Luciano, additional, Elitzur, Sarah, additional, Silvestri, Daniela, additional, Locatelli, Franco, additional, Moericke, Anja, additional, Engstler, Gernot, additional, Smisek, Petr, additional, Bodmer, Nicole, additional, Barbaric, Draga, additional, Izraeli, Shai, additional, Rizzari, Carmelo, additional, Boos, Joachim, additional, Buldini, Barbara, additional, Lanvers-Kaminsky, Claudia, additional, Cazzaniga, Giovanni, additional, Gruhn, Bernd, additional, Biondi, Andrea, additional, and Schrappe, Martin, additional

Published
2022
Full Text
View/download PDF

28. Metronomic oral maintenance chemotherapy in patients with localized high-risk rhabdomyosarcoma (RMS) and RMS-like tumors: A report from a randomized, multicenter, phase III trial CWS-2007HR.

Author

Koscielniak, Ewa, primary, Sparber-Sauer, Monika, additional, Blank, Bernd, additional, Ljungman, Gustaf, additional, Kazanowska, Bernarda, additional, Ladenstein, Ruth Lydia, additional, Niggli, Felix, additional, Boos, Joachim, additional, Handgretinger, Rupert, additional, Zimmermann, Martin, additional, von Kalle, Thekla, additional, Teichert von Luettichau, Irene, additional, Schmid, Irene, additional, Fröhlich, Birgit, additional, Müller, Hermann L., additional, Vokuhl, Christian, additional, Behnisch, Wolfgang, additional, Hallmen, Erika, additional, and Klingebiel, Thomas, additional

Published
2022
Full Text
View/download PDF

29. Erkrankungen im Kindesalter

Author

Burdach, Stefan, Groneck, Peter, Prelss, Uwe, Lentze, Michael J., Muntau, Ania C., Preiss, Uwe, Kiess, Wieland, Horneff, Gerd, Grabitz, Ralph, Schobess, Rosemarie, Brandis, Matthias, Korinthenberg, Rudole, Rauch, Frank, Schönau, Eckhard, Schweigerer, Lothar, Schranz, Dietmar, Jorch, Gerhard, Lenard, Hans-Gerd, Boos, Joachim, Herpertz-Dahlmann, Beate, Mohnike, Klaus, Schölmerich, Jürgen, editor, Burdach, Stefan, editor, Diehl, Volker, editor, Drexler, Helmut, editor, Hiddemann, Wolfgang, editor, Hörl, Walter H., editor, Klein, Helmfried, editor, Landthaler, Michael, editor, Lenz, Kurt, editor, Mann, Klaus, editor, Mössner, Joachim, editor, Müller-Ladner, Ulf, editor, Reichen, Jürg, editor, Schmiegel, Wolff, editor, Schröder, Johann Oltmann, editor, Seeger, Werner, editor, Stremmel, Wolfgang, editor, Suttorp, Norbert, editor, and Weilemann, L. Sacha, editor

Published
2003
Full Text
View/download PDF

30. New AWMF S2k guidelines Movement promotion and exercise therapy in pediatric oncology

Author

Gauss, Gabriele, Kesting, Sabine, Creutzig, Ursula, Baumann, Freerk, Boos, Joachim, Dirksen, Uta, Eckert, Katharina, Erschig, Robert, Driever, Pablo Hernaiz, Menrath, Ingo, Prokop, Aram, Schneider, Dominik, Siaplaouras, Jannos, Stalf, Hannah, Streitbuerger, Arne, Wiener, Andreas, Wiskemann, Joachim, Wittke, Torge, Goette, Miriam, Gauss, Gabriele, Kesting, Sabine, Creutzig, Ursula, Baumann, Freerk, Boos, Joachim, Dirksen, Uta, Eckert, Katharina, Erschig, Robert, Driever, Pablo Hernaiz, Menrath, Ingo, Prokop, Aram, Schneider, Dominik, Siaplaouras, Jannos, Stalf, Hannah, Streitbuerger, Arne, Wiener, Andreas, Wiskemann, Joachim, Wittke, Torge, and Goette, Miriam

Published
2022

31. Multidisciplinary Network ActiveOncoKids guidelines for providing movement and exercise in pediatric oncology: Consensus-based recommendations

Author

Goette, Miriam, Gauss, Gabriele, Dirksen, Uta, Driever, Pablo Hernaiz, Basu, Oliver, Baumann, Freerk T., Wiskemann, Joachim, Boos, Joachim, Kesting, Sabine Verena, Goette, Miriam, Gauss, Gabriele, Dirksen, Uta, Driever, Pablo Hernaiz, Basu, Oliver, Baumann, Freerk T., Wiskemann, Joachim, Boos, Joachim, and Kesting, Sabine Verena

Abstract

Background Pediatric cancer leads to reduced participation in exercise and only few patients comply with national physical activity recommendations. Physically inactive behavior hinders motor development and increases physical and psychological adverse effects of therapy and incidence of sequelae. Currently, there is neither nationwide coverage nor uniform level of knowledge regarding exercise promotion. The objective of the guideline is to facilitate qualified exercise interventions through standardized procedures in addition to regular physiotherapy and overall avoid physical inactivity in pediatric cancer patients. Methods This guideline addresses the multidisciplinary treatment team and informs physiotherapists and decision-makers in tertiary care hospitals and health insurance companies. The requirements of the Association of the Scientific Medical Societies in Germany were followed. Contents were based on best practice experience of experts, patient advocates, as well as on scientific evidence. Results The guideline includes 11 recommendations. Recommendations 1-4 declare the relevance of implementing exercise interventions and address general framework conditions. Recommendations 5-11 focus on the design of exercise programs, prevention and safety issues, relative contraindications for specific training loads, and options to overcome barriers to exercise. Conclusion This guideline summarizes existing and established structures and evidence in the context of movement and exercise in pediatric oncology. It takes into consideration the rights, varying needs, and characteristics of children and adolescents as well as national and international experience in this field. In the future, relevant research gaps need to be addressed by high-quality intervention studies to provide the scientific background for a stronger evidence-based guideline.

Published
2022

36. Pharmakologische und arzneimittelrechtliche Probleme im Kindesalter

Author

Boos, Joachim, Schölmerich, Jürgen, editor, Burdach, S., editor, Drexler, H., editor, Hallek, M., editor, Hiddemann, W., editor, Hörl, W.H., editor, Klein, H., editor, Landthaler, M., editor, Lenz, K., editor, Mann, K., editor, Mössner, J., editor, Müller-Ladner, U., editor, Reichen, J., editor, Schmiegel, W., editor, Schröder, J.O., editor, Seeger, W., editor, Stremmel, W., editor, Suttorp, N., editor, Weilemann, L.S., editor, and Wöhrle, J.C., editor

Published
2005
Full Text
View/download PDF

41. Adverse events during supervised exercise interventions in pediatric oncology - a nationwide survey

Author

Gauß, Gabriele, Beller, Ronja, Boos, Joachim, Däggelmann, Julia, Stalf, Hannah, Wiskemann, Joachim, and Götte, Miriam

Subjects
Medizinische Fakultät » Universitätsklinikum Essen » Zentrum für Kinder- und Jugendmedizin » Klinik für Kinderheilkunde III, questionnaire, physical activity, childhood cancer, oncological exercise therapy, ddc:610, adverse events
Abstract

Objectives: Exercise interventions during and after treatment for pediatric cancer are associated with beneficial physical, psychological, and social effects. However, valid data about adverse events (AEs) of such interventions have rarely been evaluated. This retrospective study evaluates AEs that occurred during supervised oncological exercise programs for pediatric cancer patients and survivors. Methods: This Germany-wide study used a self-administered online survey focusing on general program characteristics and AEs retrospectively for 2019. The questionnaire included (a) basic data on the offered exercise program, (b) AEs with consequences (Grade 2–5) that occurred in 2019 during an exercise intervention, (c) number of Grade 1 AEs, (d) safety procedures as part of the exercise programs, and (e) possibility to give feedback and describe experience with AEs in free text. Results: Out of 26 eligible exercise programs, response rate of program leaders was 92.3% ( n = 24). Representatives working for Universities ( n = 6), rehabilitation clinics ( n = 3), acute cancer clinics ( n = 12), and activity camps ( n = 3) participated. In total, 35,110 exercise interventions with varying duration were recorded for 2019. Six AEs with consequences (Grade 2–3) occurred during exercise interventions after cancer treatment resulting in an incidence of 17 per 100,000 exercise interventions (0.017%). No life-threatening consequences or death were reported and no serious AE occurred during acute cancer treatment. Grade 1 AE occurred with a frequency of 983, corresponding to an incidence of 2,800 per 100,000 interventions (2.8%). Most frequent Grade 1 AE were muscle soreness, circulatory problems, and abdominal pain. The most frequent preventive safety procedures at the institutions were regular breaks, consultations with the medical treatment team, and material selection with low injury potential. Conclusions: Supervised exercise interventions for pediatric cancer patients and survivors seem to be safe and AEs with consequences comparatively rare when compared to general childhood population data. Occurrence of grade 1 AEs was common, however, causality was probably not evident between AEs and the exercise intervention. Future research should standardize assessment of AEs in clinical practice and research, and prospectively register and evaluate AEs that occur in the context of exercise interventions in pediatric cancer patients and survivors.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results